Biodexa Pharmaceuticals Plc
BDRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001643918
No open-market purchases or sales by Biodexa Pharmaceuticals Plc insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $48.1K in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Biodexa Pharmaceuticals Plc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- −5 vs. Q2 2024
- Shares held
- 309.7K
- +158.3K (+104.5%) vs. Q2 2024
- Total value
- $87.3K
- −$48.3K (−35.6%) vs. Q2 2024
- New holders
- 1
- 4 more added
- Sold out
- 6
- 1 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BDRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $48.1K |
| Q1 2026 | 8 | $228.1K |
| Q4 2025 | 8 | $692.9K |
| Q3 2025 | 4 | $55.8K |
| Q2 2025 | 4 | $17.0K |
| Q1 2025 | 6 | $28.1K |
| Q4 2024 | 4 | $29.3K |
| Q3 2024 | 7 | $87.3K |
| Q2 2024 | 12 | $135.6K |
| Q1 2024 | 5 | $31.2K |
| Q4 2023 | 7 | $169.2K |
| Q3 2023 | 5 | $58.9K |
| Q2 2023 | 8 | $45.8K |
| Q1 2023 | 7 | $72.0K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Biodexa Pharmaceuticals Plc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 255,446 | $72.0K | 0.00% | +245,449+2,455.2% | Added |
| Two Sigma Securities, LLC | 32,577 | $9.19K | 0.00% | +12,020+58.5% | Added |
| Morgan Stanley | 14,320 | $4.04K | 0.00% | +14,304+89,400.0% | Added |
| Rhumbline Advisers | 6,038 | $1.70K | 0.00% | +3,328+122.8% | Added |
| Contravisory Investment Management, Inc. | 1,000 | $282 | 0.00% | 00.0% | Unchanged |
| GAMMA Investing LLC | 287 | $81 | 0.00% | −3,604−92.6% | Reduced |
| Hantz Financial Services, Inc. | 30 | $0 | 0.00% | +30 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −35,776−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −33,441−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −30,114−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −13,078−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −859−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |